When Angina Persists After Beta-Blocker Therapy
Add either a long-acting nitrate, amlodipine, or ivabradine to the existing beta-blocker regimen as second-line antianginal therapy.
Recommended Second-Line Options (Class I Recommendations)
When angina persists despite adequate beta-blocker therapy, the ESC guidelines provide three equally strong Class I, Level A recommendations for add-on therapy 1:
Primary Options:
- Long-acting nitrates (oral or transcutaneous) - Effective antianginal treatment with proven safety in heart failure
- Amlodipine - Effective antianginal treatment with proven safety in heart failure
- Ivabradine (if in sinus rhythm) - Effective antianginal treatment with proven safety in heart failure
All three options carry the same strength of recommendation and are supported by Level A evidence. The choice among these depends on patient-specific factors:
- Choose nitrates if the patient needs flexible dosing or has concurrent hypertension
- Choose amlodipine if the patient has hypertension or prefers once-daily dosing
- Choose ivabradine if the patient is in sinus rhythm with elevated heart rate (≥70 bpm) despite beta-blocker therapy
Alternative Second-Line Options (Weaker Evidence)
If the above options are contraindicated or not tolerated 1, 2, 3:
- Ranolazine (Class IIa-IIb) - Can be considered as add-on therapy, though safety data in heart failure patients is less robust
- Nicorandil (Class IIb) - May be considered, but safety in heart failure is uncertain
Critical Contraindications to Avoid
Do NOT use diltiazem or verapamil in patients with heart failure or LV systolic dysfunction (Class III, Level B) 1 - these non-dihydropyridine calcium channel blockers have negative inotropic effects and risk worsening heart failure.
Algorithmic Approach
Step 1: Ensure beta-blocker is optimally dosed before adding second agent
Step 2: Add one of the three Class I options (nitrate, amlodipine, or ivabradine) based on:
- Heart rhythm (ivabradine requires sinus rhythm)
- Blood pressure status
- Comorbidities (especially heart failure)
- Patient preference for dosing frequency
Step 3: If angina persists on two antianginal drugs, proceed to coronary revascularization evaluation (Class I, Level A) 1
Important Caveats
- Avoid certain combinations: Do not combine ivabradine, ranolazine, and nicorandil together due to unknown safety (Class III) 1
- Avoid nitrate + nicorandil combination due to lack of additional efficacy (Class III) 1
- The 2024 ESC guidelines 2 and 2023 AHA/ACC guidelines 3 continue to support this stepwise approach, with ranolazine gaining slightly more traction as add-on therapy in recent years
- For patients with unstable angina or acute presentations, the approach differs and requires more aggressive initial management 4
The evidence strongly supports that you should not wait - persistent angina on beta-blocker monotherapy warrants immediate addition of a second antianginal agent rather than uptitrating the beta-blocker indefinitely.